Metamizol Basi (Metamizole Sodium Monohydrate)

Metamizole inhibits cyclooxygenase enzymes, decreasing prostaglandin synthesis, and also modulates central spinal pathways, providing combined analgesic and antipyretic effects without the typical gastrointestinal impact of many NSAIDs.

The specific dose and administration schedule of Metamizol Basi are determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. No standard dosing is provided here.

Safety data for Metamizole in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Metamizole offers analgesic and antipyretic effects similar to NSAIDs but with a lower incidence of gastrointestinal irritation. However, it carries a rare risk of agranulocytosis, which is less common with many other analgesic classes, so risk‑benefit assessment is essential.

Metamizol Basi should be stored below 25 °C, in its original packaging, protected from light and moisture. Do not freeze the product, and keep it out of reach of children.

The medication is supplied as a sterile injectable solution and may be given intramuscularly or intravenously by a qualified healthcare professional, following aseptic technique and appropriate dilution if required.

The most serious adverse reactions include agranulocytosis, anaphylactic shock, Stevens‑Johnson syndrome, and severe liver injury. Immediate medical attention is required if signs of these conditions appear.

Patients with known hypersensitivity to pyrazolones, a history of agranulocytosis, severe liver or kidney impairment, or those receiving concurrent myelosuppressive therapy should avoid Metamizol Basi unless specifically directed by a physician.